companiesCompany
RhoVac
aka RhoVac AB, Chosa Oncology
RhoVac was a Swedish biotech whose peptide vaccine RV001 trained T cells against RhoC, a protein of spreading cancer cells, but its phase 2b trial in prostate cancer failed in 2022.
Overview
RhoVac developed RV001 (onilcamotide), a peptide vaccine against the small GTPase RhoC, which is over-expressed in metastasising cancer cells but not in the primary tumour. The randomised phase 2b BRaVac trial tested RV001 to delay progression in men with rising PSA after prostatectomy or radiotherapy; it did not reach its endpoint in 2022, and the company wound down the programme and was later renamed Chosa Oncology to pursue other assets.
Headquarters
Lund, SE
Scorecard
All companies#430of 1181 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
biotech
Stage
Wound down